Skip to content
Log in
Sponsored AI AM CLAUDE, A Beginner's Guide: Learn the basics of working with AI AI AM CLAUDE, A Beginner's Guide: Learn the basics of working with AI

Author

N. Tannir

h-index 80 View on Semantic Scholar

We have 3 of 783 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Aug 2026

Panitumumab-Based EGFR Blockade in SMARCB1-Deficient Renal Medullary Carcinoma: Preclinical Basis and Prospective Clinical Activity

Purpose: SMARCB1-deficient renal medullary carcinoma (RMC) is an ultra-rare, lethal malignancy refractory to therapies approved for other renal cell carcinomas, and its rarity makes randomized trials logistically unfeasible. We investigated whether wild-type epidermal growth factor receptor (EGFR) is a therapeutically...

N. Zacharias, Eric S Rupe, Xinyue Chen et al. · 0 citations
Open access Sep 2026

25 Phase II Trial of Sacituzumab Tirumotecan in Patients with SMARCB1-Deficient Renal Medullary Carcinoma Previously Treated with at Least One Prior Line of Therapy: STaRMC Trial (NCT07438626)

It is hypothesized that sacituzumab tirumotecan will produce a potent and durable antitumor response in patients with RMC who develop progressive disease on at least one prior line of therapy.

P. Msaouel, Rebecca S. Slack-Tidwell, R. Sheth et al. · 0 citations
Open access Jul 2026

Allogeneic CD70-Targeted Chimeric Antigen Receptor T-Cell Therapy for Advanced Renal Cell Carcinoma: Results From the Phase I TRAVERSE Trial

The TRAVERSE trial demonstrates proof of concept for the role of allogeneic CAR T-cell therapy in solid tumors and had manageable safety and encouraging antitumor activity in CD70-positive ccRCC.

S. Srour, J. Chahoud, A. Drakaki et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.